tiprankstipranks
Advertisement
Advertisement
Aligos Therapeutics Licenses Hepatitis B Drug Rights to Amoytop
PremiumCompany AnnouncementsAligos Therapeutics Licenses Hepatitis B Drug Rights to Amoytop
2M ago
Aligos Therapeutics signs license deal to develop pevifoscorvir in China
Premium
The Fly
Aligos Therapeutics signs license deal to develop pevifoscorvir in China
3M ago
Aligos Therapeutics: Data-Driven Phase 2 Update Supports Buy Rating and $50 Target on Pevifoscorvir’s HBV Opportunity
Premium
Ratings
Aligos Therapeutics: Data-Driven Phase 2 Update Supports Buy Rating and $50 Target on Pevifoscorvir’s HBV Opportunity
3M ago
Aligos Therapeutics reports Q4 EPS ($1.91), consensus ($2.49)
PremiumThe FlyAligos Therapeutics reports Q4 EPS ($1.91), consensus ($2.49)
4M ago
ALGS Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ALGS Earnings this Week: How Will it Perform?
4M ago
Aligos Advances Hepatitis B Candidate With New Renal Safety Study, Keeping Long-Term Upside in Play
Premium
Company Announcements
Aligos Advances Hepatitis B Candidate With New Renal Safety Study, Keeping Long-Term Upside in Play
4M ago
Aligos Therapeutics announces resignation of Chief Medical Officer Achneck
PremiumThe FlyAligos Therapeutics announces resignation of Chief Medical Officer Achneck
5M ago
Aligos Therapeutics management to meet virtually with Piper Sandler
Premium
The Fly
Aligos Therapeutics management to meet virtually with Piper Sandler
5M ago
Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market
Premium
Company Announcements
Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100